The research community often moves by methods, maybe as much as it moves by questions

Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc

I don’t disagree with your theme but in context if that quote it’s worth remembering that Pharma usually outputs antibodies to drug targets

It could still be 500 slides. But presented at the speed of his brain!

“Cry, the beloved country, these things are not yet at an end”

Alan Paton

Your users can simply choose on price/performance

Regardless of the results, why would you NOT offer PIPseq as a service given not barriers to start this protocol?

Where illumina could struggle culturally is to do product development beyond the current somalogic kit going around. They indicate this so let’s see

I think it’s an old perception that illumina reps can only sell boxes. Illumina run rate is pretty high per instruments and they are less focused on new sites but upgrading and developing business around each sequencer

In all cases you already know that library prep balloons well above sequencing costs compared to classic methods illumina is already doing prep kits for

Like with spatial and single cell, they don’t need to, do they? They just need a bigger slice of the library prep pie

You’re a bright star in this sky. Keep posting!!

So you can hide a wedding ring in there and…

Were you not allowed to enter the mass spec conference? 🤣

You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you

The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission

- Don’t screen for a collection of unrelated diseases
- Target an area that has clinical pathway already and accompanies existing test
- Focus on identifying patients for more attention not less
- Don’t target PCPs
- Utility cannot be “live healthier”